ZBH Stock Forecast & Price Target

Zimmer Biomet Holdings has demonstrated a strong presence in the orthopedic reconstructive market, evidenced by a global market share increase of 20 basis points year-over-year, reaching 32.9%. Sales in key product lines, particularly knees and hips, surpassed consensus estimates with knee sales of $911 million showing a growth rate of 6.9% and hip sales of $555 million growing by 4.9%, indicating an upward trend in demand. Furthermore, operational margin (OM) expansion from 28.6% in FY24 suggests improved profitability, reinforcing a favorable outlook for the company.

The analysis indicates a negative outlook on Zimmer Biomet Holdings due to a sustained decline in organic revenue growth, with expectations that this trend will persist into 2026, potentially weakening overall financial performance. Key issues include underwhelming contributions from the recently acquired Paragon 28 and disappointing sales from new product launches such as the ROSA robot, which may limit any growth potential. Furthermore, the company's operating margin has decreased by 170 basis points year-over-year, driven by rising selling, general, and administrative expenses, raising concerns about profitability amid a challenging market environment.